Kryeziu K, Klokkerud SK, Totland MZ, Moosavi SH, Reims HM, Bergsland CH, Eilertsen IA, Smeby J, Lassen K, Lundesgaard KK, Syversveen T, Brændengen M, Nesbakken A, Guren TK, Yaqub S, Sveen A, Lothe RA (2026)
Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity
Cell Rep Med, 102840 (in press)
DOI 10.1016/j.xcrm.2026.102840, PubMed 42208542

Sveen A, Bergsland CH, Niederdorfer B, Berstad AE, Bjerkehagen B, Boye K, Guren TK, Lothe RA (2026)
Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial
NPJ Precis Oncol, 10 (1)
DOI 10.1038/s41698-026-01303-6, PubMed 41760889

Morken S, Langer SW, Hjortland GO, Sundlöv A, Hofsli E, Ladekarl M, Tabaksblat E, Vestermark LW, Svensson J, Knigge U, Nunes L, Glimelius B, Pfeiffer P, Aasebø K, Assmus J, Vassella E, Lothe IMB, Couvelard A, Perren A, Knappskog S, Sorbye H (2026)
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
Int J Cancer, 158 (12), 3217-3231
DOI 10.1002/ijc.70367, PubMed 41642024